Evaluation of the interfractional biological effective dose (BED) variation in MammoSite high dose rate brachytherapy

The objective of this work is to evaluate the interfractional biological effective dose (BED) variation in MammoSite high dose rate (HDR) brachytherapy. Dose distributions of 19 patients who received 34 Gy in 10 fractions were evaluated. A method was employed to account for nonuniform dose distribution in the BED calculation. Furthermore, a range of α/β values was utilized for specific clinical end points: fibrosis, telangiectasia, erythema, desquamation and breast carcinoma. Two scenarios were simulated to calculate the BED value using: i) the same dose distribution of fraction 1 over fractions 2–10 (constant case, CC), and ii) the actual delivered dose distribution for each fraction 1–10 (interfraction dose variation case, IVC). Although the average BED difference (IVC – CC) was [Formula: see text] Gy for all clinical endpoints, the range of difference for fibrosis and telangiectasia reached [Formula: see text] to [Formula: see text] and [Formula: see text] to [Formula: see text] for one of the patients, respectively. By disregarding high inhomogeneity in HDR brachytherapy, the conventional BED calculation tends to overestimate the BED for fibrosis by 16% on average, while it underestimates the BED for erythema (7.6%) and desquamation (10.2%). In conclusion, the BED calculation accounting for the nonuniform dose distribution provides a more clinically relevant description of the clinical delivered dose. Though the average BED difference was clinically insignificant, the maximum difference of BED for late effects can differ by a single fractional dose (10%) for a specific patient due to the interfraction dose variation in MammoSite treatment. PACS number: 87.53.Jw